MHRA sets out approach to strengthen patient and public involvement and engagement in medicines and medical device regulation
What was announced
New plan will broaden participation and make clearer how patient experience informs regulatory decisions, safety and innovation
Key points, in the publisher's words
- Patients and the public will have a greater role in shaping medicines and medical device regulation under a new plan published today by the Medicines and Healthcare products Regulatory Agency (MHRA).
- The Patient and Public Involvement and Engagement Plan 2026–2030 (PPIE) , a key tenet of the MHRA’s Strategy 2030, sets out how the agency will involve and engage people earlier, hear from a wider range of patient groups and communities and explain openly and clearly how patients’ experiences shape its work.
- Patients’ lived experience will help inform decisions at the MHRA, including the assessment of medicine benefits and risks, safety reviews, regulatory policy, patient information and the development of regulatory approaches for rare diseases, medical devices, future regulatory pathways, artificial intelligence (AI) and other emerging technologies.
Who and where
UK bodies of power
- Medicines and Healthcare products Regulatory Agency (executive agency) · more news
- National Institute for Health and Care Excellence (executive non-departmental public body) · more news
Where this sits in the 10 levels of power
Topics, as GOV.UK files them: Good practice, inspections and enforcement.
Receipt
- Original: https://www.gov.uk/government/news/mhra-sets-out-approach-to-strengthen-patient-and-public-involvement-and-engagement-in-medicines-and-medical-device-regulation
- Published 2026-11-05 16:00:04 UTC
- Read by this site 2026-11-05 16:00:45 UTC from GOV.UK
- Saved copy: receipt 8668, with its SHA-256 fingerprint
Contains public sector information licensed under the Open Government Licence v3.0.
Related official news
- MHRA guidance on its assessment of non-clinical data generated outside OECD system
- Clinical trials for medicines: Inclusion and Diversity Plan pilot findings published
- MHRA launches patient safety essay competition for MedSafetyWeek
- Triheptanoin (Dojolvi) approved to treat adults and children with a group of rare inherited disorders
- MHRA approves gene-editing treatment for children aged five and over with serious inherited blood disorders
- New MHRA research puts needle-free Strep A vaccine within reach
- MHRA approves deuruxolitinib (Leqselvi) to treat severe alopecia areata in adults
- MHRA approves new oral treatment for moderate to severe plaque psoriasis
More from GOV.UK
- Investigation over risk to multi-million pound charity property
- 53rd Universal Periodic Review of human rights: UK Statement on Tanzania
- Continued violations of Abyei’s demilitarised status are unacceptable: UK statement at the UN Security Council
- Man who murdered Henry Nowak has sentence increased
- UK veteran support centre network to more than double
- Joint Statement by the Informal Group of Friends of Safety of Journalists, November 2026
Also announced on 5 November 2026
- First EMT Global Meeting in Africa advances commitment to sustainable national teams
- Bank rate increased to 4% - November 2026 Monetary Policy Summary and Minutes
- Two new Ebola vaccines to join DR Congo clinical trial
- Security Council, 10266th Meeting (AM) Sudan, South Sudan
- Security Council, 10265th Meeting (AM) Yemen
- Isabel Schnabel: Navigating stormy waters: reflections on monetary policy